On May 19, BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE:NVO) following the announcement of a CEO transition. Analysts view the ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S ...

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...

But whereas Novo Nordisk’s GLP-1 mimetic semaglutide (Ozempic, Wegovy) and Eli Lilly’s dual GLP-1/GIP receptor agonist tirzepatide (Mounjaro, Zepbound) have since taken the cardiometabolic ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Seigerman acknowledged that Novo Nordisk's experimental small-molecule pill, amycretin, could be competitive long term. But he said that won't happen soon, as the drug is not expected to launch ...